Latest News and Press Releases

ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør årsrapport for 2023 torsdag den 8. februar 2024 om eftermiddagen. ALK afholder samme dag kl. 16.00 (CET) en telekonference for investorer og...

ALK (ALKB:DC / OMX: ALK B / AKBLF) meddelte i dag, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn er accepteret til vurdering af de...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ACARIZAX® (house dust mite sublingual immunotherapy tablet) in young children has been accepted for review by...

  Studiet fortsætter nu i sin anden del, som forventes afsluttet senere i 2024.ALK indsender protokolændring for at udvide studiet til et fase 1-2 effektstudie. ALK (ALKB:DC / OMX: ALK B / AKBLF)...

The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK (ALKB:DC / OMX: ALK B /...

– PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii – The Danish, pharmaceutical company ALK (ALKB:DC /...

Finanskalender 2024 for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11. januar 2024: Stilleperiode8. februar 2024: Offentliggørelse af årsrapport 202314. marts 2024 kl. 16.00: Ordinær generalforsamling...

  2024 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11 January 2024: Silent period        8 February 2024: Annual report 2023         14 March 2024 at 4.00 p.m.: Annual...

ALK (ALKB:DC / OMX: ALK B / AKBLF) og selskabets japanske partner Torii Pharmaceutical Co., Ltd. (’Torii’) meddeler i dag, at de har udvidet samarbejdet og har indgået yderligere en licensaftale, der...

ALK (ALKB:DC / OMX: ALK B / AKBLF) and its Japanese partner Torii Pharmaceutical Co., Ltd. ('Torii') today announced that they have expanded their collaboration and entered into an additional license...